NASHUA, N.H., April 8, 2024 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today that announced new data showing that its AI-powered solution effectively detects cancer. Calcium deposits in breast blood vessels are a sign of possible cardiovascular disease in women. Chirag Parghi, MD, iCAD research collaborator and chief medical officer of Solis Mammography, will be speaking at the American College of Cardiology (ACC) Annual Meeting, April 6-8, 2024 in Atlanta, Georgia. The results of this research were presented.

For this study, Dr. Pargi and his team used iCAD’s ProFound AI Heart Health to include mammograms from a multiracial cohort of 117,189 women.^I A solution specifically designed for thoracic artery calcification (BAC) detection. The 15-center prospective study included 2D screening mammograms in women aged 20 to 100 years with a median age of 56 years.

“The ProFound BAC AI algorithm has the potential to provide an important alternative biomarker for women at risk for heart disease and stroke,” said Dana Brown, President and CEO of iCAD. “We are excited to collaborate with Solis Mammography on this cutting-edge software that can tell women early on if they are at potential risk for heart disease during routine mammography exams. provides women with valuable information that may lead to additional cardiovascular testing. We believe that ProFound Heart We hope that Health will have a positive impact on the prevention of cardiovascular disease in women.”

Dr. Pargi and his team analyzed data from a prospective study of 117,189 women and found the overall prevalence of BAC (score > 1) to be 14.8%. Prevalence increases with age, with a prevalence of 4.2% in women younger than 50 years, a prevalence of 9.0% in women aged 50 to 59 years, and a prevalence of 19.9% ​​in women aged 60 to 69 years. The prevalence among women aged 70 years and older was 40.7%. . Future efforts include longitudinally following patients to identify associated cardiovascular risk factors and guiding primary care physicians in the management of patients with detected BAC. This study also suggests that the ProFound Heart Health AI algorithm could standardize her BAC detection, improve efficiency, and reduce interobserver variability. These findings are consistent with previous literature highlighting the association between BAC and cardiovascular risk and highlight the potential of BAC detection in screening mammography for women’s health.

“Using artificial intelligence software, breast artery calcification can be detected with high accuracy,” Dr. Pargi said. “This tool allows us to identify patients who would benefit from additional cardiovascular screening, potentially allowing us to intervene before adverse outcomes occur. One screening mammogram can reduce the two leading causes of death in women. It’s amazing that we can gain such meaningful insights into breast cancer and heart disease.”

“Currently, radiologists must rely on visual detection of breast artery calcification, which is time consuming and leads to consistent underreporting of BAC results,” continued Dr. Pargi. “The AI ​​algorithm’s accurate identification of his BAC will result in more consistent detection and reporting of his BAC, ultimately providing the greatest benefit to the patient.”

Recent studies have shown that calcium deposits in blood vessels in the breast are correlated with stiffening of cardiovascular arteries, and women with BAC are 51% more likely to develop heart disease. Early detection of cardiovascular disease is key because in asymptomatic women, the first symptom of underlying coronary heart disease is often acute myocardial infarction (MI) or sudden death. Although women tend to have a lower burden of obstructive coronary artery disease on angiography, they typically have a poorer prognosis after MI compared to men.

About iCAD Co., Ltd.
iCAD, Inc. (NASDAQ: ICAD) delivers clinically proven, AI-powered solutions that enable healthcare providers to accurately and reliably detect cancer early and improve patient outcomes. We are a global leader on a mission to create a world where cancer is no longer hidden. Headquartered in Nashua, New Hampshire, iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment, and risk assessment. ProFound is used by thousands of providers serving millions of patients and is available in more than 50 countries. iCAD estimates that in the past five years alone he has read more than 40 million mammograms worldwide, of which nearly 30% were tomosynthesis. For more information, including the latest regulatory approvals, please visit www.icadmed.com.

Forward-looking statements
Certain statements contained in this news release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. This includes statements regarding expanded access to our products, improved performance, accelerated adoption and expected benefits. ProFound AI®, the benefits of our products, and the future prospects of our technology platform and products; Such forward-looking statements involve a number of known and unknown risks that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by us. , uncertainties, and other factors. Such a positive statement. These factors include our ability to achieve our business and strategic goals, patient willingness to undergo mammography screening given the risk of potential exposure to COVID-19, and whether mammography screening is considered an essential procedure. This includes, but is not limited to, whether the , whether ProFound AI proves to improve read efficiency, improve specificity and sensitivity, reduce false positives, or otherwise be more beneficial to patients and clinicians, supply and manufacturing constraints; the impact of risks and difficulties on our ability to fulfill orders, the level of uncertainty regarding future sales, our defense in litigation matters, the protection of our patents and other proprietary rights, the market acceptance of our products, the potential technical obsolescence of our products; the effects of increased competition, changes in government regulations, Medicare or other reimbursement policies, risks associated with our existing and future obligations, competitive factors and declines in the economies or markets we serve; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “plan”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking statements. . Readers are cautioned not to place undue reliance on these forward-looking statements. These statements speak only as of the date on which they are made. We undertake no obligation to provide updates to the information contained in this release. For additional disclosures regarding these and other risks faced by iCAD, please see the disclosures contained in our public filings with the Securities and Exchange Commission. This document is available from the “Investors” section of our website at http://www.icadmed.com and from the SEC. Website http://www.sec.gov.

contact address

Media inquiries: pr@icadmed.com
Investor inquiries: ir@icadmed.com

^I The Breast Artery Calcification Assessment is pending regulatory approval and is available for research purposes only.